- Home
- BTBD vs KPRX Comparison
BTBD vs KPRX Comparison
Compare BTBD & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTBD
- KPRX
- Stock Information
- Founded
- BTBD 1987
- KPRX 1998
- Country
- BTBD United States
- KPRX United States
- Employees
- BTBD N/A
- KPRX N/A
- Industry
- BTBD Restaurants
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BTBD Consumer Discretionary
- KPRX Health Care
- Exchange
- BTBD Nasdaq
- KPRX Nasdaq
- Market Cap
- BTBD 9.7M
- KPRX 10.0M
- IPO Year
- BTBD 2021
- KPRX N/A
- Fundamental
- Price
- BTBD $1.38
- KPRX $3.29
- Analyst Decision
- BTBD
- KPRX Strong Buy
- Analyst Count
- BTBD 0
- KPRX 1
- Target Price
- BTBD N/A
- KPRX $10.00
- AVG Volume (30 Days)
- BTBD 5.8K
- KPRX 47.9K
- Earning Date
- BTBD 11-13-2024
- KPRX 11-08-2024
- Dividend Yield
- BTBD N/A
- KPRX N/A
- EPS Growth
- BTBD N/A
- KPRX N/A
- EPS
- BTBD N/A
- KPRX 1.69
- Revenue
- BTBD $14,647,844.00
- KPRX $16,020,000.00
- Revenue This Year
- BTBD N/A
- KPRX N/A
- Revenue Next Year
- BTBD N/A
- KPRX N/A
- P/E Ratio
- BTBD N/A
- KPRX $1.93
- Revenue Growth
- BTBD 4.20
- KPRX N/A
- 52 Week Low
- BTBD $1.25
- KPRX $3.00
- 52 Week High
- BTBD $3.05
- KPRX $8.98
- Technical
- Relative Strength Index (RSI)
- BTBD 35.37
- KPRX 44.86
- Support Level
- BTBD $1.33
- KPRX $3.08
- Resistance Level
- BTBD $1.64
- KPRX $4.04
- Average True Range (ATR)
- BTBD 0.11
- KPRX 0.28
- MACD
- BTBD -0.02
- KPRX -0.02
- Stochastic Oscillator
- BTBD 13.80
- KPRX 21.88
About BTBD BT Brands Inc.
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. The company also operates in Minnesota as a franchisee of Dairy Queen. It offers a variety of burgers and other affordably priced foods such as chicken sandwiches, pulled pork sandwiches, chicken chunks, side dishes, and soft drinks.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.